Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
17.53
+0.75 (4.47%)
At close: Jun 18, 2026, 4:00 PM EDT
17.70
+0.17 (0.97%)
After-hours: Jun 18, 2026, 7:50 PM EDT
Adaptive Biotechnologies Revenue
Adaptive Biotechnologies had revenue of $70.87M in the quarter ending March 31, 2026, with 35.14% growth. This brings the company's revenue in the last twelve months to $295.41M, up 55.87% year-over-year. In the year 2025, Adaptive Biotechnologies had annual revenue of $276.98M with 54.77% growth.
Revenue (ttm)
$295.41M
Revenue Growth
+55.87%
P/S Ratio
9.50
Revenue / Employee
$473,409
Employees
624
Market Cap
2.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 276.98M | 98.02M | 54.77% |
| Dec 31, 2024 | 178.96M | 8.68M | 5.10% |
| Dec 31, 2023 | 170.28M | -15.03M | -8.11% |
| Dec 31, 2022 | 185.31M | 30.96M | 20.06% |
| Dec 31, 2021 | 154.34M | 55.96M | 56.88% |
| Dec 31, 2020 | 98.38M | 13.31M | 15.65% |
| Dec 31, 2019 | 85.07M | 29.41M | 52.83% |
| Dec 31, 2018 | 55.66M | 17.22M | 44.77% |
| Dec 31, 2017 | 38.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 2.14B |
| Sotera Health Company | 1.19B |
| NeoGenomics | 745.97M |
| OPKO Health | 581.12M |
| Veracyte | 541.74M |
| GeneDx Holdings | 442.68M |
| CareDx | 412.82M |
| Twist Bioscience | 409.48M |
ADPT News
- 1 day ago - Adaptive Biotechnologies prices $300M convertible senior note offering - TheFly
- 1 day ago - Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering - GlobeNewsWire
- 2 days ago - Adaptive Biotechnologies management to meet with Craig-Hallum - TheFly
- 2 days ago - Adaptive Biotechnologies offers to sell $250M in 2031 convertible senior notes - TheFly
- 3 days ago - Adaptive Biotechnologies plans separation of immune medicine platform - Reuters
- 3 days ago - Adaptive to plans to separate minimal residual disease, immune medicine segments - TheFly
- 3 days ago - Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses - GlobeNewsWire
- 3 days ago - Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering - GlobeNewsWire